NASDAQ:PTIE - Pain Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$10.15 -0.26 (-2.50 %)
(As of 05/21/2018 08:54 AM ET)
Previous Close$10.41
Today's Range$10.12 - $10.58
52-Week Range$3.10 - $12.80
Volume39,000 shs
Average Volume469,115 shs
Market Capitalization$69.99 million
P/E RatioN/A
Dividend YieldN/A
Beta2.53

About Pain Therapeutics (NASDAQ:PTIE)

Pain Therapeutics logoPain Therapeutics, Inc. develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease. The company was founded in 1998 and is based in Austin, Texas.

Receive PTIE News and Ratings via Email

Sign-up to receive the latest news and ratings for PTIE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PTIE
CUSIP69562K10
Phone512-501-2444

Debt

Debt-to-Equity RatioN/A
Current Ratio14.51
Quick Ratio14.51

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.47 per share
Price / Book6.90

Profitability

EPS (Most Recent Fiscal Year)($1.82)
Net Income$-11,910,000.00
Net MarginsN/A
Return on Equity-101.55%
Return on Assets-93.41%

Miscellaneous

Employees9
Outstanding Shares6,900,000

Pain Therapeutics (NASDAQ:PTIE) Frequently Asked Questions

What is Pain Therapeutics' stock symbol?

Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE."

When did Pain Therapeutics' stock split? How did Pain Therapeutics' stock split work?

Pain Therapeutics's stock reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Pain Therapeutics stock prior to the reverse split would have 14 shares after the split.

How were Pain Therapeutics' earnings last quarter?

Pain Therapeutics, Inc (NASDAQ:PTIE) announced its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.66) by $0.33. View Pain Therapeutics' Earnings History.

When is Pain Therapeutics' next earnings date?

Pain Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Pain Therapeutics.

Who are some of Pain Therapeutics' key competitors?

Who are Pain Therapeutics' key executives?

Pain Therapeutics' management team includes the folowing people:
  • Mr. Remi Barbier, Founder, Chairman, CEO, Pres & Principal Financial Officer (Age 58)
  • Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 75)
  • Mr. Michael J. O'Donnell, Sec. & Director (Age 60)
  • Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs

Has Pain Therapeutics been receiving favorable news coverage?

Headlines about PTIE stock have been trending positive on Monday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pain Therapeutics earned a coverage optimism score of 0.48 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.62 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Pain Therapeutics' major shareholders?

Pain Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Northern Trust Corp (0.55%). View Institutional Ownership Trends for Pain Therapeutics.

Which major investors are buying Pain Therapeutics stock?

PTIE stock was bought by a variety of institutional investors in the last quarter, including Northern Trust Corp. View Insider Buying and Selling for Pain Therapeutics.

How do I buy shares of Pain Therapeutics?

Shares of PTIE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pain Therapeutics' stock price today?

One share of PTIE stock can currently be purchased for approximately $10.15.

How big of a company is Pain Therapeutics?

Pain Therapeutics has a market capitalization of $69.99 million. The biopharmaceutical company earns $-11,910,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. Pain Therapeutics employs 9 workers across the globe.

How can I contact Pain Therapeutics?

Pain Therapeutics' mailing address is 7801 NORTH CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The biopharmaceutical company can be reached via phone at 512-501-2444.


MarketBeat Community Rating for Pain Therapeutics (PTIE)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  213
MarketBeat's community ratings are surveys of what our community members think about Pain Therapeutics and other stocks. Vote "Outperform" if you believe PTIE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTIE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pain Therapeutics (NASDAQ:PTIE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Pain Therapeutics in the last 12 months. There are currently 1 sell rating for the stock, resulting in a consensus rating of "Sell."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: SellSellSellSell
Consensus Rating Score: 1.001.001.001.00
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Pain Therapeutics (NASDAQ:PTIE) Consensus Price Target History

Price Target History for Pain Therapeutics (NASDAQ:PTIE)

Pain Therapeutics (NASDAQ:PTIE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017GabelliDowngradeHold ➝ SellLowView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Pain Therapeutics (NASDAQ:PTIE) Earnings History and Estimates Chart

Earnings by Quarter for Pain Therapeutics (NASDAQ:PTIE)

Pain Therapeutics (NASDAQ:PTIE) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.65 EPS
Next Year EPS Consensus Estimate: $-4.85 EPS

Pain Therapeutics (NASDAQ PTIE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018N/AView Earnings Details
5/9/2018Q1 2018($0.66)($0.33)ViewN/AView Earnings Details
2/5/2018Q4 2017($0.37)ViewN/AView Earnings Details
11/1/2017Q3 2017($0.40)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.47)($0.64)ViewN/AView Earnings Details
4/25/2017Q1 2017($0.42)($0.42)ViewN/AView Earnings Details
2/17/2017Q4 2016($0.42)ViewN/AView Earnings Details
10/20/2016Q316($0.63)($0.56)ViewN/AView Earnings Details
7/19/2016Q216($0.98)($0.49)ViewN/AView Earnings Details
5/5/2016Q1($0.70)($0.91)ViewN/AView Earnings Details
3/1/2016Q4 2015($0.70)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.56)ViewN/AView Earnings Details
7/23/2015Q2 2015($0.49)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.42)ViewN/AView Earnings Details
2/17/2015Q4 2014($0.35)ViewN/AView Earnings Details
10/30/2014Q314($0.56)$89.70 millionViewN/AView Earnings Details
8/5/2014Q214($0.49)ViewN/AView Earnings Details
5/6/2014Q1 14($0.42)($0.56)$1.96 millionViewN/AView Earnings Details
2/4/2014Q413($0.07)$5.04$2.00 million$35.24 millionViewN/AView Earnings Details
10/31/2013Q313($0.07)($0.14)$2.00 million$1.96 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.07)($0.07)$1.96 millionViewN/AView Earnings Details
4/24/2013Q1 2013($0.07)($0.07)$2.80 million$1.96 millionViewN/AView Earnings Details
2/6/2013Q4 2012($0.14)($0.56)$2.79 million$2.47 millionViewN/AView Earnings Details
11/8/2012Q3 2012($0.07)($0.21)ViewN/AView Earnings Details
8/2/2012Q2 2012($0.02)ViewN/AView Earnings Details
5/8/2012Q1 2012($0.07)$0.01ViewN/AView Earnings Details
2/9/2012Q4 2011($0.14)($0.06)ViewN/AView Earnings Details
11/3/2011Q3 2011($0.14)($0.13)ViewN/AView Earnings Details
8/4/2011Q2 2011($0.14)($0.19)ViewN/AView Earnings Details
2/3/2011Q4 2010($1.50)ViewN/AView Earnings Details
10/28/2010Q3 2010$0.49($0.17)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.21)($0.14)ViewN/AView Earnings Details
4/28/2010Q1 2010($0.17)ViewN/AView Earnings Details
1/28/2010Q4 2009($0.28)($0.05)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.49)($0.22)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.28)($0.01)ViewN/AView Earnings Details
4/30/2009Q1 2009($0.14)($0.30)ViewN/AView Earnings Details
2/5/2009Q4 2008$0.28($0.22)ViewN/AView Earnings Details
10/29/2008Q3 2008$2.10$2.47ViewN/AView Earnings Details
7/30/2008Q2 2008$0.70($0.17)ViewN/AView Earnings Details
5/7/2008Q1 2008$0.42$0.40ViewN/AView Earnings Details
2/7/2008Q4 2007$0.21$0.17ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Pain Therapeutics (NASDAQ:PTIE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/11/2012special$5.2512/13/201212/17/201212/24/2012
(Data available from 1/1/2013 forward)

Insider Trades

Pain Therapeutics (NASDAQ PTIE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 31.40%
Institutional Ownership Percentage: 32.97%
Insider Trading History for Pain Therapeutics (NASDAQ:PTIE)
Institutional Ownership by Quarter for Pain Therapeutics (NASDAQ:PTIE)

Pain Therapeutics (NASDAQ PTIE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/6/2013Sanford RobertsonDirectorBuy50,000$3.73$186,500.00369,727View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pain Therapeutics (NASDAQ PTIE) News Headlines

Source:
DateHeadline
Cara Therapeutics to Present at the International Investigative Dermatology 2018 MeetingCara Therapeutics to Present at the International Investigative Dermatology 2018 Meeting
www.nasdaq.com - May 14 at 5:36 PM
Pain Therapeutics (PTIE) Issues  Earnings Results, Beats Expectations By $0.33 EPSPain Therapeutics (PTIE) Issues Earnings Results, Beats Expectations By $0.33 EPS
www.americanbankingnews.com - May 10 at 9:53 PM
Pain Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update on REMOXY® ERPain Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update on REMOXY® ER
finance.yahoo.com - May 9 at 8:11 AM
New Research on the Global Osteoarthritis Pain Drugs Market |TechnavioNew Research on the Global Osteoarthritis Pain Drugs Market |Technavio
www.businesswire.com - May 4 at 5:47 PM
Pain Therapeutics (PTIE) Upgraded to Hold at ValuEnginePain Therapeutics (PTIE) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - May 2 at 7:06 PM
Pain Therapeutics (PTIE) Stock Rating Lowered by Zacks Investment ResearchPain Therapeutics (PTIE) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 18 at 11:44 AM
Gabelli Downgrades Pain Therapeutics (PTIE) to SellGabelli Downgrades Pain Therapeutics (PTIE) to Sell
www.americanbankingnews.com - April 17 at 11:28 PM
Pain Therapeutics (PTIE) Shares March Higher, Can It Continue?Pain Therapeutics (PTIE) Shares March Higher, Can It Continue?
finance.yahoo.com - April 12 at 5:44 PM
Acclaimed Scientists and Physicians Join the Scientific Advisory Board of SiteOne Therapeutics to Help Guide the ...Acclaimed Scientists and Physicians Join the Scientific Advisory Board of SiteOne Therapeutics to Help Guide the ...
www.prnewswire.com - April 6 at 8:03 AM
Pain Therapeutics (PTIE) Raised to "Buy" at Zacks Investment ResearchPain Therapeutics (PTIE) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 3 at 9:18 PM
Post-Operative Pain Therapeutics Pipeline to Witness Many Technological Advancements in the Coming Years: P&S ...Post-Operative Pain Therapeutics Pipeline to Witness Many Technological Advancements in the Coming Years: P&S ...
globenewswire.com - March 31 at 5:40 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Pain Therapeutics, Inc. for Potential Breaches ... - PR Newswire (press release)SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Pain Therapeutics, Inc. for Potential Breaches ... - PR Newswire (press release)
www.prnewswire.com - March 21 at 8:06 AM
Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY ER® - GlobeNewswire (press release)Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY ER® - GlobeNewswire (press release)
globenewswire.com - March 20 at 8:02 AM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Pain Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Pain Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
www.prnewswire.com - March 19 at 7:49 AM
Pain Therapeutics (PTIE) Upgraded by Zacks Investment Research to "Buy"Pain Therapeutics (PTIE) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - March 14 at 6:48 AM
Analyst: Durects Phase 2 Trials Are An Entry Point For InvestorsAnalyst: Durect's Phase 2 Trials Are An Entry Point For Investors
finance.yahoo.com - March 6 at 5:32 PM
Pain Therapeutics (PTIE) Downgraded by ValuEnginePain Therapeutics (PTIE) Downgraded by ValuEngine
www.americanbankingnews.com - March 4 at 11:38 AM
Pain Therapeutics (PTIE) REMOXY NDA Accepted by FDA, Sets August 7 PDUFA Date - StreetInsider.comPain Therapeutics (PTIE) REMOXY NDA Accepted by FDA, Sets August 7 PDUFA Date - StreetInsider.com
www.streetinsider.com - March 3 at 5:36 PM
Pain Therapeutics (PTIE) REMOXY NDA Accepted by FDA, Sets August 7 PDUFA DatePain Therapeutics (PTIE) REMOXY NDA Accepted by FDA, Sets August 7 PDUFA Date
www.streetinsider.com - March 2 at 8:23 AM
How Should You Think About Pain Therapeutics Inc’s (NASDAQ:PTIE) Risks?How Should You Think About Pain Therapeutics Inc’s (NASDAQ:PTIE) Risks?
finance.yahoo.com - March 1 at 5:46 PM
FDA Accepts REMOXY® NDA for Review, Sets PDUFA Date of August 7, 2018FDA Accepts REMOXY® NDA for Review, Sets PDUFA Date of August 7, 2018
finance.yahoo.com - March 1 at 8:30 AM
Pain Therapeutics (PTIE) Lowered to Hold at Zacks Investment ResearchPain Therapeutics (PTIE) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 24 at 4:30 PM
Pain Therapeutics (PTIE) Upgraded at Zacks Investment ResearchPain Therapeutics (PTIE) Upgraded at Zacks Investment Research
www.americanbankingnews.com - February 22 at 9:56 AM
Gabelli Weighs in on Pain Therapeutics, Inc.s FY2018 Earnings (PTIE)Gabelli Weighs in on Pain Therapeutics, Inc.'s FY2018 Earnings (PTIE)
www.americanbankingnews.com - February 16 at 11:18 AM
Gabelli Comments on Pain Therapeutics, Inc.s FY2022 Earnings (PTIE)Gabelli Comments on Pain Therapeutics, Inc.'s FY2022 Earnings (PTIE)
www.americanbankingnews.com - February 15 at 4:28 PM
TTPH Implodes On IGNITE3, EC Approves 2nd Herceptin Biosimilar, PTIE At It Again - NasdaqTTPH Implodes On IGNITE3, EC Approves 2nd Herceptin Biosimilar, PTIE At It Again - Nasdaq
www.nasdaq.com - February 14 at 3:34 PM
Pain Therapeutics (PTIE) Resubmits NDA for REMOXY ER - StreetInsider.comPain Therapeutics (PTIE) Resubmits NDA for REMOXY ER - StreetInsider.com
www.streetinsider.com - February 14 at 7:38 AM
Pain Therapeutics Resubmits New Drug Application for REMOXY® ER, an Abuse-Deterrent, Extended-Release Drug Candidate for the Treatment of Chronic PainPain Therapeutics Resubmits New Drug Application for REMOXY® ER, an Abuse-Deterrent, Extended-Release Drug Candidate for the Treatment of Chronic Pain
finance.yahoo.com - February 13 at 3:30 PM
Pain Therapeutics refiles U.S. marketing application for Remoxy ER; shares up 3%Pain Therapeutics refiles U.S. marketing application for Remoxy ER; shares up 3%
seekingalpha.com - February 13 at 9:57 AM
Pain Therapeutics (PTIE) to Release Quarterly Earnings on ThursdayPain Therapeutics (PTIE) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - February 8 at 1:24 AM
Pain Therapeutics Reports 2017 Financial Results and Corporate Update - GlobeNewswire (press release)Pain Therapeutics Reports 2017 Financial Results and Corporate Update - GlobeNewswire (press release)
globenewswire.com - February 6 at 7:22 AM
Pain Therapeutics Reports 2017 Financial Results and Corporate UpdatePain Therapeutics Reports 2017 Financial Results and Corporate Update
finance.yahoo.com - February 5 at 3:29 PM
Quotidian Technical Highlights on Selected Biotech Stocks -- PDL BioPharma, Progenics Pharma, Pain Therapeutics, and uniQureQuotidian Technical Highlights on Selected Biotech Stocks -- PDL BioPharma, Progenics Pharma, Pain Therapeutics, and uniQure
www.bizjournals.com - January 19 at 11:38 AM
Gabelli Analysts Raise Earnings Estimates for Pain Therapeutics, Inc. (PTIE)Gabelli Analysts Raise Earnings Estimates for Pain Therapeutics, Inc. (PTIE)
www.americanbankingnews.com - January 12 at 6:54 AM
Zacks: Pain Therapeutics, Inc. (PTIE) Given Average Rating of "Strong Sell" by BrokeragesZacks: Pain Therapeutics, Inc. (PTIE) Given Average Rating of "Strong Sell" by Brokerages
www.americanbankingnews.com - January 10 at 5:30 PM
Earnings Growth Hamper Pain Therapeutics (PTIE) RatingEarnings Growth Hamper Pain Therapeutics (PTIE) Rating
investorplace.com - January 10 at 11:18 AM
PTIE Skyrockets On Remoxy Data, ASND On An Ascent, There Is HOPE For GBTPTIE Skyrockets On Remoxy Data, ASND On An Ascent, There Is HOPE For GBT
www.finanznachrichten.de - January 10 at 10:17 AM
Does Pain Therapeutics Inc’s (NASDAQ:PTIE) Earnings Growth Make It An Outperformer?Does Pain Therapeutics Inc’s (NASDAQ:PTIE) Earnings Growth Make It An Outperformer?
finance.yahoo.com - January 10 at 10:17 AM
Pain Therapeutics, REMOXY Gets Positive Study Results, Updates for FENROCK and PTI-125Pain Therapeutics, REMOXY Gets Positive Study Results, Updates for FENROCK and PTI-125
finance.yahoo.com - January 10 at 10:17 AM
Here’s What’s Moving Axsome Therapeutics and Pain TherapeuticsHere’s What’s Moving Axsome Therapeutics and Pain Therapeutics
finance.yahoo.com - January 10 at 10:17 AM
2 Biotech Stocks Climbing on Positive Findings - Baystreet.ca2 Biotech Stocks Climbing on Positive Findings - Baystreet.ca
www.baystreet.ca - January 9 at 4:46 PM
Mid-Afternoon Market Update: Pain Therapeutics Jumps On Clinical Study Data; Big 5 Sporting Goods Shares Plummet - BenzingaMid-Afternoon Market Update: Pain Therapeutics Jumps On Clinical Study Data; Big 5 Sporting Goods Shares Plummet - Benzinga
www.benzinga.com - January 9 at 4:46 PM
Pain Therapeutics Shares Double On Clinical Study Data - BenzingaPain Therapeutics Shares Double On Clinical Study Data - Benzinga
www.benzinga.com - January 9 at 4:46 PM
2 Biotech Stocks Climbing on Positive Findings2 Biotech Stocks Climbing on Positive Findings
finance.yahoo.com - January 9 at 4:46 PM
Why Pain Therapeutics, Inc. (PTIE) Shares Skyrocketed 150% TodayWhy Pain Therapeutics, Inc. (PTIE) Shares Skyrocketed 150% Today
finance.yahoo.com - January 9 at 4:46 PM
Healthcare Stocks Breakout: Pain Therapeutics, Inc. (PTIE), Global Blood Therapeutics Inc (GBT)Healthcare Stocks Breakout: Pain Therapeutics, Inc. (PTIE), Global Blood Therapeutics Inc (GBT)
finance.yahoo.com - January 9 at 4:46 PM
Mid-Afternoon Market Update: Pain Therapeutics Jumps On Clinical Study Data; Big 5 Sporting Goods Shares PlummetMid-Afternoon Market Update: Pain Therapeutics Jumps On Clinical Study Data; Big 5 Sporting Goods Shares Plummet
feeds.benzinga.com - January 9 at 3:31 PM
Durect up 11% on Pain Therapeutics Remoxy-stoked rallyDurect up 11% on Pain Therapeutics' Remoxy-stoked rally
seekingalpha.com - January 9 at 12:56 PM
Pain Therapeutics Shares Double On Clinical Study DataPain Therapeutics Shares Double On Clinical Study Data
feeds.benzinga.com - January 9 at 12:32 PM
Pain Therapeutics Reports Positive Top-line Results from Nasal Abuse Potential Study with REMOXY™Pain Therapeutics Reports Positive Top-line Results from Nasal Abuse Potential Study with REMOXY™
finance.yahoo.com - January 9 at 10:07 AM

SEC Filings

Pain Therapeutics (NASDAQ:PTIE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pain Therapeutics (NASDAQ:PTIE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pain Therapeutics (NASDAQ PTIE) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.